Melanotan II
Also known as: MT-II, MT-2, Melanotan 2
Summary
Melanotan II is a synthetic alpha-MSH analog that stimulates melanin production — tanning without UV. It activates all five melanocortin receptors non-selectively, which explains both its range of effects and its broad side-effect profile. It has never been approved in any country.
Key Findings at a Glance
- • Melanotan II is a non-selective melanocortin receptor agonist that simultaneously affects pigmentation, sexual function, appetite, and inflammation through MC1R through MC5R activation.
- • Melanotan II produces UV-independent tanning by directly stimulating melanocytes to produce eumelanin, the protective dark pigment, without requiring sun exposure.
- • The sexual arousal effects observed with Melanotan II directly led to the development of PT-141, a more targeted derivative that became the first FDA-approved peptide for sexual dysfunction.
- • Melanotan II has a notably broad side effect profile including nausea and facial flushing precisely because it lacks selectivity and activates all five melanocortin receptor subtypes.
Melanotan II Overview & Molecular Profile
Melanotan II is a cyclic lactam analog of alpha-melanocyte stimulating hormone (α-MSH) developed at the University of Arizona by Hruby et al. in the late 1980s. It is a non-selective pan-melanocortin agonist activating MC1R (pigmentation), MC3R/MC4R (sexual function and appetite), and MC5R—producing multiple simultaneous biological effects. Its sexual arousal side effect discovered during tanning trials led to the development of PT-141 (Bremelanotide), the only FDA-approved derivative. Melanotan II itself has no approved clinical indication.
Mechanism of Action: Receptor Agonism & Metabolic Pathways
Melanotan II is a non-selective melanocortin receptor agonist, affecting MC1R (pigmentation), MC3R, MC4R (sexual function, appetite), and MC5R. By activating MC1R on melanocytes, it stimulates melanin production. Its effects on MC3R and MC4R influence sexual behavior and appetite regulation.
Melanotan II Pharmacokinetics: A Cyclic Peptide Built for Stability, Measured Mostly in Rodents
Melanotan II's cyclic lactam scaffold gives it far greater protease resistance than linear α-MSH, but formal human pharmacokinetic parameters have never been published. The quantitative PK literature is rodent-based: rapid plasma clearance, low brain penetration, and broad tissue distribution mapped by mass spectrometry imaging. Human data consists of a single Phase I subcutaneous dose-escalation study that measured pigmentation response rather than plasma kinetics.
Rodent PK: Rapid Plasma Clearance
Dedicated analytical studies in rats and mice consistently show the peptide disappearing from plasma quickly after parenteral administration.
- • Rat IV Kinetics: An LC/MS/MS assay with a 5 ng/mL limit of quantitation enabled the first formal determination of melanotan II pharmacokinetic parameters in rat plasma following intravenous administration (PMID 12415547).
- • Mouse Clearance: After intraperitoneal administration of 1 mg/kg in mice, clearance of melanotan II from plasma was rapid, quantifiable down to a 0.5 ng/mL lower limit of quantitation (PMID 17610239).
- • No Human Half-Life on Record: No peer-reviewed study reports a human plasma half-life for melanotan II. The roughly one-hour figure repeated across secondary sources traces to rodent plasma data, not human measurement — the cyclic structure improves stability over linear α-MSH but does not produce a long-acting compound.
Tissue Distribution and the Brain-Penetration Question
Melanotan II's centrally-mediated effects (appetite, arousal, nausea) raised a genuine distribution puzzle, because quantitative data shows the peptide barely crosses into brain tissue.
- • Low CNS Penetration: In mice, brain homogenate concentrations reached only 11.4 ± 5.5 ng/g at 30 minutes post-dose despite high simultaneous plasma levels, confirming low brain penetrability and leaving open whether central effects occur at circumventricular sites outside the blood-brain barrier (PMID 17610239).
- • Whole-Body Mapping: MALDI mass spectrometry imaging combined with droplet-based surface sampling has been used to map the molecular distribution of melanotan II and its metabolites across whole-body tissue sections, establishing it as a model cyclic peptide for ADME method development (PMID 32674774).
- • Receptor-Mediated Targeting: Distribution is shaped less by passive diffusion than by melanocortin receptor expression — MC1R on melanocytes drives pigmentary uptake of the drug's action, while MC3R/MC4R in hypothalamic and brainstem nuclei mediate the metabolic and behavioral effects observed at low brain concentrations.
Human Data and the Melanotan-I Contrast
The closest thing to human PK characterization comes from the Phase I tanning trial, and from the approved linear analog afamelanotide (Melanotan-I), whose profile was defined far more rigorously.
- • Phase I SC Dosing: The 1996 pilot Phase I study administered escalating subcutaneous melanotan II doses of 0.01–0.03 mg/kg, producing dose-dependent increases in skin melanin — evidence of substantial subcutaneous bioactivity, though plasma concentrations were not reported (PMID 8637402).
- • Afamelanotide Benchmark: For the linear analog afamelanotide, subcutaneous injection showed full bioavailability while neither oral nor transdermal application produced measurable plasma concentrations or pigmentation response — establishing the route-dependence expected for this peptide class (PMID 28063031).
- • The Sustained-Release Solution: Afamelanotide's clinical development solved the short half-life problem with a controlled-release subcutaneous implant effective at lower total dose than daily saline injections; no equivalent formulation work exists for melanotan II (PMID 28063031).
Research-Observed Effects
Melanogenesis
Extensive ResearchResearch demonstrates Melanotan II's potent melanogenic effects through direct activation of melanocortin-1 receptors (MC1R) on melanocytes, triggering increased tyrosinase activity and eumelanin production that results in progressive skin darkening. Clinical studies have documented significant increases in melanin index scores within 2-4 weeks of administration, with enhanced tanning response to UV exposure and photoprotection research applications. The peptide induces melanin synthesis through cyclic AMP pathway activation, phosphorylation of CREB transcription factors, and upregulation of melanogenesis-related genes including MITF and TYR. Research has shown that Melanotan II can produce visible skin pigmentation changes even without sun exposure, though UV radiation synergistically enhances the tanning effect and provides more natural appearance outcomes. These melanogenesis promotion properties have significant implications for skin pigmentation research, photoprotection mechanism studies, and understanding the molecular basis of melanin production for potential vitiligo treatment applications and sun damage prevention investigations.
Sexual Function Effects
Moderate ResearchExtensive research demonstrates Melanotan II's pronounced pro-sexual effects through activation of melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) in hypothalamic nuclei controlling sexual behavior and arousal. Clinical studies in both men and women have documented increased spontaneous erections, enhanced libido, and improved sexual satisfaction scores following subcutaneous administration of the peptide. The sexual enhancement effects occur through central nervous system mechanisms independent of peripheral vascular changes, involving activation of oxytocinergic pathways and modulation of dopamine signaling in reward-related brain circuits. Research has shown onset of sexual function effects within 1-3 hours of administration, with duration of action extending up to 72 hours in some study subjects, making it distinct from fast-acting vasodilator treatments. These findings have positioned Melanotan II as an important research compound for investigating central regulation of sexual function, libido enhancement mechanisms, and the neurobiological connections between melanocortin signaling and sexual motivation pathways.
Appetite Modulation
Moderate ResearchResearch indicates Melanotan II produces significant appetite-suppressing effects through activation of melanocortin-4 receptors (MC4R) located in the paraventricular nucleus and other hypothalamic regions controlling food intake and energy balance. Animal studies have demonstrated reduced food consumption, decreased body weight gain, and altered feeding behaviors following chronic Melanotan II administration, with effects mediated through the central melanocortin-leptin signaling axis. The peptide's anorectic properties appear to involve modulation of neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons that normally stimulate appetite, creating a shift toward reduced hunger signals. Clinical observations have noted decreased appetite and potential weight management effects in human subjects receiving Melanotan II for other research purposes. These appetite regulation effects have generated interest in melanocortin pathway research for obesity treatment development, eating disorder mechanisms, and understanding the complex neuroendocrine control of energy homeostasis and metabolic health improvement.
Fat Metabolism Effects
Preliminary ResearchEmerging research suggests Melanotan II may influence fat metabolism through melanocortin receptor activation in both central and peripheral tissues, with studies documenting effects on lipolysis and adipocyte function. Animal research has shown MC4R activation increases sympathetic nervous system activity to adipose tissue, promoting fatty acid release and oxidation through enhanced beta-adrenergic signaling pathways. Studies indicate the peptide may preferentially affect visceral fat stores, which have higher melanocortin receptor expression than subcutaneous adipose depots, suggesting potential applications in abdominal fat reduction research. Research has documented increased energy expenditure and thermogenesis in treated animals, contributing to negative energy balance independent of appetite suppression effects. These fat metabolism optimization properties position Melanotan II as a research tool for investigating melanocortin-mediated metabolic regulation, body composition modification mechanisms, and the development of novel approaches to obesity and metabolic syndrome research.
Research Protocol Doses Reported in Published Literature
Research Disclaimer: Doses reported below are from published preclinical research protocols. Melanotan II is not approved for human use by the FDA or any regulatory agency. This information is provided for research reference only and does not constitute a dosing recommendation.
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| Subcutaneous | 0.25–1 mg | As needed or daily (per research protocol) | Higher doses cause more severe nausea; clinical studies typically used 0.025 mg/kg |
All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.
Research Studies & References
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study
Dorr RT, Lines R, Levine N, et al.
Life Sciences (1996)
This pioneering clinical study evaluated Melanotan II's dual effects on skin pigmentation and erectile function in healthy male volunteers, establishing the foundation for melanocortin peptide research in both dermatology and sexual medicine. Researchers administered escalating subcutaneous doses ranging from 0.01 to 0.025 mg/kg and documented dose-dependent increases in skin melanin content measured by spectrophotometry, with visible tanning occurring within days of treatment initiation. The study simultaneously observed spontaneous penile erections in multiple subjects independent of sexual stimulation, leading to the unexpected discovery of Melanotan II's pro-erectile properties mediated through central melanocortin pathways. Analysis of side effect profiles identified transient nausea, facial flushing, and fatigue as common dose-limiting factors, informing subsequent dosing optimization research. These findings established Melanotan II as a multi-functional melanocortin agonist and led to the development of PT-141 (Bremelanotide) as a sexual dysfunction-focused derivative peptide.
The melanocortin-1 receptor and human pigmentation
Abdel-Malek Z, Suzuki I, Tada A, Im S, Akcali C
Annals of the New York Academy of Sciences (1999)
This review examines the melanocortin-1 receptor (MC1R) and its role in human pigmentation, providing the mechanistic rationale for why superpotent MC1R agonists such as Melanotan II darken skin. The authors describe how alpha-MSH and ACTH exert similar mitogenic and melanogenic effects on cultured human epidermal melanocytes, and how activation of this receptor stimulates eumelanin synthesis, as in the homologous mouse receptor. Stimulation of the cAMP pathway is identified as a key driver of the melanogenic response, and MC1R activation is described as pivotal for UV-induced melanogenesis. The review also explains that agouti signaling protein competes with alpha-MSH at the MC1R, reducing basal tyrosinase activity and shifting synthesis toward pheomelanin. Allelic variants of the MC1R gene are noted to be associated with red hair, poor tanning ability, and possibly melanoma, underscoring the receptor's central role in pigmentation and photoprotection.
Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization
Hadley ME, Dorr RT
Peptides (2006)
This comprehensive review by two of the pioneers of melanocortin peptide research traces the development of Melanotan II from initial discovery through clinical testing. The authors document the historical milestones from isolation of alpha-MSH through design of superpotent cyclic analogs, and summarize Phase I clinical data demonstrating dose-dependent skin darkening and pro-erectile effects in human subjects. The review discusses the pharmacological rationale for melanocortin receptor targeting, structure-activity relationships that informed Melanotan II design, and the subsequent development of PT-141 (bremelanotide) as a derivative optimized for sexual dysfunction. Safety data from clinical studies are summarized, including common adverse effects of nausea, facial flushing, and fatigue at higher doses. The paper provides essential context for understanding Melanotan II's position as the parent compound from which multiple clinical candidates were derived.
Comparative Research
Explore in-depth research analyses and comparative studies featuring Melanotan II.
Frequently Asked Questions
What is the difference between Melanotan I and Melanotan II?
Melanotan I (afamelanotide) is a linear peptide with MC1R selectivity, primarily affecting pigmentation. It has FDA/EMA approval (as Scenesse) for erythropoietic protoporphyria (EPP), a photosensitivity disorder. Melanotan II is a cyclic peptide with non-selective agonism across MC1R–MC5R, producing simultaneous effects on pigmentation (MC1R), sexual function (MC3R/MC4R), appetite (MC4R), and inflammation (MC1R, MC3R). MT-II has more diverse effects but also significantly more side effects (nausea, facial flushing, spontaneous erections/arousal) due to its receptor non-selectivity.
How was PT-141 discovered from Melanotan II research?
During Phase 1 tanning trials with Melanotan II at the University of Arizona in the 1990s, male subjects reported unexpected spontaneous erections and sexual arousal as a side effect. Researchers recognized this as evidence that MC3R/MC4R activation mediates sexual response. This serendipitous finding was deliberately pursued by removing the amide group from Melanotan II to create PT-141 (Bremelanotide)—a modified analog retaining sexual function effects while being less likely to cause blood pressure elevation. PT-141 subsequently underwent full clinical development and received FDA approval in 2019.
Is Melanotan II legal or approved for use?
Melanotan II is not approved by the FDA, EMA, or any major regulatory agency for any clinical indication. It is classified as a research chemical in most jurisdictions. Its sale for human use is prohibited in many countries including the UK, Australia, Canada, and the European Union. The FDA has issued multiple warnings against its use due to safety concerns including reports of melanoma activation, severe nausea, and cardiovascular effects. This is distinct from Melanotan I (afamelanotide/Scenesse), which is approved for EPP.
What side effects does Melanotan II cause?
Due to its non-selective agonism across all five melanocortin receptors, Melanotan II has a broad side effect profile: nausea and vomiting (common, especially at higher doses), facial flushing, spontaneous erections/arousal regardless of intent, transient increases in blood pressure, appetite suppression, fatigue, and darkening of existing moles/nevi (which raises concerns about melanoma risk). The nausea occurs via MC3R/MC4R activation in the area postrema (brain's vomiting center). The risk-benefit profile has prevented regulatory approval.
Can Melanotan II actually produce a tan without sun exposure?
Yes, in research settings, subcutaneous Melanotan II administration has produced visible skin darkening without UV exposure by directly stimulating MC1R on melanocytes to increase eumelanin production. Studies document measurable melanin index increases within 2–4 weeks. However, the tanning produced without UV exposure differs from UV-induced tanning in distribution and appearance, and does not necessarily provide equivalent photoprotection. Afamelanotide (Melanotan I/Scenesse) is the approved and studied peptide for UV-independent photoprotection in EPP patients.
What appetite-suppressing research has been conducted with Melanotan II?
Melanotan II is a potent appetite suppressant in animal models via MC4R activation in the hypothalamic arcuate nucleus. Rodent studies show 30–50% reductions in food intake and significant body weight reductions. However, no human trials specifically studying appetite suppression with MT-II have been published—the nausea side effect may confound any appetite-suppression measurement (vomiting reduces caloric intake independently of true satiety signaling). The MC4R pathway implicated by MT-II research has been validated by human genetic studies: loss-of-function MC4R mutations are the most common single-gene cause of severe human obesity, confirming the receptor's physiological importance for weight regulation.
What are the safety concerns that prevented Melanotan II from reaching clinical approval?
Several safety signals prevented Melanotan II's clinical development: (1) Cardiovascular: dose-dependent hypertension and tachycardia at higher doses via sympathetic activation; (2) Nausea: a near-universal side effect via area postrema MC3R activation, limiting therapeutic windows; (3) Melanocytic risk: case reports of rapid changes in existing nevi and potential melanoma activation following MT-II use; skin safety monitoring is inadequate in uncontrolled use; (4) Non-selectivity: off-target effects across all five MCRs makes selective pharmacological effect impossible with this molecule; (5) Route of administration: subcutaneous injection requirement limited consumer adoption compared to oral alternatives. These issues collectively prevented the risk-benefit balance required for regulatory approval.
How does Melanotan II's mechanism compare to afamelanotide (Scenesse)?
Afamelanotide (Melanotan I/Scenesse) is an MC1R-selective linear peptide with an extended half-life (~40 hours via implant delivery). It targets only MC1R on melanocytes, producing photoprotective tanning without affecting MC3R or MC4R—meaning no sexual effects, no appetite changes, and minimal nausea. MT-II's cyclic structure and non-selectivity mean it hits all five MCRs simultaneously. Afamelanotide represents what pharmaceutical optimization achieved by taking the MT-II research direction and creating a selective, safe molecule. MT-II is essentially the crude prototype from which afamelanotide was scientifically refined.
Related Peptides
View allPT-141
PT-141 (Bremelanotide) is a synthetic peptide that acts on melanocortin receptors. It was developed from the tanning peptide Melanotan II and has been studied for sexual dysfunction.
Melanotan I (Afamelanotide)
Melanotan I (afamelanotide) is a linear alpha-MSH analog with predominant melanocortin-1 receptor activity, FDA-approved in 2019 as Scenesse, a 16 mg subcutaneous implant, to increase pain-free light exposure in adults with erythropoietic protoporphyria.